Opinion paper on utility of point-of-care biomarkers in the emergency department pathways decision making

Clinical Chemistry and Laboratory Medicine

Volumn 52, Issue 10, 2014, Pages 1401-1407

  Di Somma, Salvatore ^a   Zampini, Giorgio ^a   Vetrone, Francesco ^a   Soto Ruiz, Karina M ^b   Magrini, Laura ^a   Cardelli, Patrizia ^a   Ronco, Claudio ^c   Maisel, Alan ^d   Peacock, Frank W ^b  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b BAYLOR COLLEGE OF MEDICINE   (United States)

^c SAN BORTOLO HOSPITAL   (Italy)

^d UCSD MEDICAL CENTER   (United States)

Author keywords

Brain natriuretic peptide (BNP); Neutrophil gelatinase associated lipocalin (NGAL); Point of care testing (POCT); Troponin

Indexed keywords

BRAIN NATRIURETIC PEPTIDE; NEUTROPHIL GELATINASE ASSOCIATED LIPOCALIN; TROPONIN; ACUTE PHASE PROTEIN; BIOLOGICAL MARKER; LCN2 PROTEIN, HUMAN; LIPOCALIN; ONCOPROTEIN;

ACUTE CORONARY SYNDROME; COMPARATIVE STUDY; CROWDING (AREA); DECISION MAKING; DIAGNOSTIC PROCEDURE; EMERGENCY WARD; HEART FAILURE; HOSPITALIZATION; HUMAN; KIDNEY INJURY; LABORATORY TEST; POINT OF CARE TESTING; PRIORITY JOURNAL; REVIEW; SENSITIVITY AND SPECIFICITY; BLOOD; EMERGENCY HEALTH SERVICE; HOSPITAL INFORMATION SYSTEM; UTILIZATION;

ACUTE-PHASE PROTEINS; BIOLOGICAL MARKERS; DECISION MAKING; EMERGENCY SERVICE, HOSPITAL; HUMANS; LIPOCALINS; NATRIURETIC PEPTIDE, BRAIN; POINT-OF-CARE SYSTEMS; PROTO-ONCOGENE PROTEINS; TROPONIN;

EID: 84921352131     PISSN: 14346621     EISSN: 14374331     Source Type: Journal    
DOI: 10.1515/cclm-2014-0267     Document Type: Review

References (44)

1. Gaze D, Collinson PO, Haass M, Derhaschnig U, Hirschl MM, Katus HA, et al. The use of a quantitative point-of-care system greatly reduces the turnaround time of cardiac marker determination. POC 2004;3:156-8. http://journals.lww.com/poctjournal/ Abstract/2004/12000/The-Use-of-a-Quantitative-Point-of- Care-System.3.aspx.
2. Herring A, Wilper A, Himmelstein D, Woolhandler S, Espinola J, Brown D, et al. Increasing length of stay among adult visits to U.S. emergency departments, 2001-2005. Acad Emerg Med 2009;16:609-16.
3. Guttmann A, Schull MJ, Vermeulen MJ, Stukel TA. Association between waiting times and short term mortality and hospital admission after departure from emergency department: population based cohort study from Ontario, Canada. Br Med J 2011;342:d2983.
4. Goodacre S, Cross E, Arnold J, Angelini K, Capewell S, Nicholl J. The health care burden of acute chest pain. Heart 2005;91:229-30.
5. Wuerz RC, Meador SA. Effects of prehospital medications on mortality and length of stay in congestive heart failure. Ann Emerg Med 1992;21:669-74.
6. McCord J, Nowak RM, McCullough PA, Foreback C, Borsak S, Tokarski G, et al. Ninety-minute exclusion of acute myocardial infarction by use of quantitative point-of-care testing of myoglobin and troponin I. Circulation 2001;104:1483-8.
7. Storrow AB, Zhou C, Gaddis G, Han JH, Miller K, Klubert D, et al. Decreasing lab turnaround time improves emergency department throughput and decreases emergency medical services diversion: a simulation model. Acad Emerg Med 2008;15:1130-5.
8. Takakuwa KM, Ou FS, Peterson ED, Pollack CV Jr, Peacock WF, Hoeskstra JW, et al. The usage patterns of cardiac bedside markers employing point-of-care testing for troponin in non- ST-segment elevation acute coronary syndrome: results from CRUSADE. Clin Cardiol 2009;32:498-505.
9. Koehler J, Flarity K, Hertner G, Aker J, Stout JP, Gifford M, et al. Effect of troponin I point-of-care testing on emergency department throughput measures and staff satisfaction. Adv Emerg Nurs J 2013;35:270-7.
10. Soremekun OA, Datner EM, Banh S, Becker LB, Pines JM. Utility of point-of-care testing in ED triage. Am J Emerg Med 2013;31:291-6.
11. Apple FS, Adrine Chung Y, Kogut ME, Bubany S, Murakami MA. Decreased patient charges following implementation of pointof- care cardiac troponin monitoring in acute coronary syndrome patients in a community hospital cardiology unit. Clin Chim Acta 2006;375:191-5.
12. Thygesen K, Alpert JS, Jaffe AS, Simoons ML, Chaitman BR, White MD, et al. Third universal definition of myocardial infarction. J Am Coll Cardiol 2012;60:1581-98.
13. Jaffe AS. Chasing troponin: how low can you go if you can see the rise? J Am Coll Cardiol 2006;48:1763-4.
14. Apple FS, Jesse RL, Newby LK, Wu AH, Christenson RH; National Academy of Clinical Biochemistry; IFCC Committee for Standardization of Markers of Cardiac Damage. National Academy of Clinical Biochemistry and IFCC Committee for standardization of markers of cardiac damage laboratory medicine practice guidelines: analytical issues for biochemical markers of acute coronary syndromes. Circulation 2007;115:e352-5.
15. Thygesen K, Mair J, Giannitsis E, Mueller C, Lindahl B, Blankenberg S, et al. Study group on biomarkers in cardiology of the ESC working group on acute cardiac care. How to use highsensitivity cardiac troponins in acute cardiac care. Eur Heart J 2012;33:2252-7.
16. Than M, Cullen L, Reid CM, Lim SH, Aldous S, Ardagh MW, et al. A 2-h diagnostic protocol to assess patients with chest pain symptoms in the Asia-Pacific region (ASPECT): a prospective observational validation study. Lancet 2011;377:1077-84.
17. Cullen L, Mueller C, Parsonage WA, Wildi K, Greenslade JH, Twerenbold R, et al. Validation of high-sensitivity troponin I in a 2-hour diagnostic strategy to assess 30-day outcomes in emergency department patients with possible acute coronary syndrome. J Am Coll Cardiol 2013;62:1242-9.
18. Diercks DB, Peacock WF 4th, Hollander JE, Singer AJ, Birkhahn R, Shapiro N, et al. Diagnostic accuracy of a point-of-care troponin I assay for acute myocardial infarction within 3 hours after presentation in early presenters to the emergency department with chest pain. Am Heart J 2012;163:74-80.
19. Braunwald E. Biomarkers in heart failure. N Engl J Med 2008;358:2148-59.
20. Silver MA, Maisel A, Yancy CW, McCullough PA, Burnett JC Jr, Francis GS, et al. BNP consensus Panel 2004: a clinical approach for the diagnostic, prognostic, screening, treatment monitoring, and therapeutic roles of natriuretic peptides in cardiovascular diseases. Congest Heart Fail 2004;10(5 Suppl 3):1-30.
21. Ichiki T, Burnett J. A new signal from BNP in STEMI: what does it mean for BNP and innovative diagnostics? Circulation 2010;122:229-32.
22. Daniels LB, Maisel AS. Natriuretic peptides. J Am Coll Cardiol 2007;50:2357-68.
23. Maisel A, Mueller C, Adams K Jr, Anker SD, Aspromonte N, Cleland JG, et al. State of the art: using natriuretic peptide levels in clinical practice. Eur J Heart Fail 2008;10:824-39.
24. McMurray JJ, Adamopoulos S, Anker SD, Auricchio A, Böhm M, Dickstein K, et al. ESC guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur J Heart Fail 2012;14:803-69.
25. Maisel AS, Clopton P, Krishnaswamy P, Nowak RM, McCord J, Hollander JE, et al. Impact of age, race, and sex on the ability of B-type natriuretic peptide to aid in the emergency diagnosis of heart failure: results from the Breathing Not Properly (BNP) multinational study. Am Heart J 2004;147:1078-84.
26. Peacock WF, Emerman C, Costanzo MR, Diercks DB, Lopatin M, Fonarow GC. Early vasoactive drugs improve heart failure outcomes. Congest Heart Fail 2009;15:256-64.
27. Disomma S, Magrini L, Pittoni V, Marino R, Peacock WF, Maisel A. Usefulness of serial assessment of natriuretic peptides in the emergency department for patients with acute decompensated heart failure. Congest Heart Fail 2008;14(4 Suppl 1):21-4.
28. Peacock WF, Emerman CL, Costanzo MR, Diercks DB, Lopatin M, Fonarow GC, et al. Early initiation of IV vasoactive therapy improves heart failure outcome: an analysis from the ADHERE registry database. Ann Emerg Med 2003;42:526.
29. McCullough PA. Nowak RM, McCord J, Hollander JE, Herrmann HC, Steg PG, et al. B-type natriuretic peptide and clinical judgment in emergency diagnosis of heart failure: analysis from breathing not properly (BNP) multinational study. Circulation 2002;106:416-22.
30. Mueller C, Laule-Kilian K, Schindler C, Kilma T, Frana B, Rodriguez D, et al. Cost-effectiveness of B-type natriuretic peptide testing in patients with acute dyspnea. Arch Intern Med 2006;166:1081-7.
31. Di Somma S, Magrini L, Pittoni V, Marino R, Mastrantuono A, Ferri E, et al. In-hospital percentage BNP reduction is highly predictive for adverse events in patients admitted for acute heart failure: the Italian RED Study. Crit Care 2010;14:R116.
32. Kociol R, Horton J, Fonarow G, Reyes EM, Shaw LK, O'Connor CM, et al. Admission, discharge, or change in B-type natriuretic peptide and long-term outcome: data from Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients with Heart Failure (OPTIMIZE-HF) linked to Medicare claims. Circ Heart Fail 2011;4:628-36.
33. Mishra J, Mori K, Ma Q, Kelly C, Barasch J, Devarajan P. Neutrophil gelatinase-associated lipocalin: a novel early urinary biomarker for cisplatin nephrotoxicity. Am J Nephrol 2004;24:307-15.
34. Mori K, Nakao K. Neutrophil gelatinase-associated lipocalin as the real-time indicator of active kidney damage. Kidney Int 2007;71:967-70.
35. Hirsch R, Dent C, Pfriem H, Allen J, Beekman RH 3rd, Ma Q, et al. NGAL is an early predictive biomarker of contrast-induced nephropathy in children. Pediatr Nephrol 2007;22:2089-95.
36. Shapiro NI, Trzeciak S, Hollander JE, Birkhahn R, Otero R, Osborn TM, et al. The diagnostic accuracy of plasma neutrophil gelatinase-associated lipocalin in the prediction of acute kidney injury in emergency department patients with suspected sepsis. Ann Emerg Med 2010;56:52-9,e1.
37. Devarajan P. Emerging biomarkers of acute kidney injury. Contrib Nephrol 2007;156:203-12.
38. Mishra J, Dent C, Tarabishi R, Mitsnefes MM, Ma Q, Kelly C, et al. Neutrophil gelatinase-associated lipocalin (NGAL) as a biomarker for acute renal injury after cardiac surgery. Lancet 2005;365:1231-8.
39. Peacock WF, Maisel A, Kim J, Ronco C. Neutrophil gelatinase associated lipocalin in acute kidney injury. Postgrad Med 2013;125:82-93.
40. Nickolas TL, O'Rourke MJ, Yang J, Sise ME, Canetta PA, Barasch N, et al. Sensitivity and specificity of a single emergency department measurement of urinary neutrophil gelatinase-associated lipocalin for diagnosing acute kidney injury. Ann Intern Med 2008;148:810-9.
41. Bagshaw SM, Bennett M, Haase M, Haase-Fielitz A, Egi M, Morimatsu H, et al. Plasma and urine neutrophil gelatinase-associated lipocalin in septic versus non-septic acute kidney injury in critical illness. Intensive Care Med 2010;36:452-61.
42. Di Somma S, Magrini L, De Berardinis B, Marino R, Ferri E, Moscatelli P, et al. Additive value of blood neutrophil gelatinase associated lipocalin to clinical judgement in acute kidney injury diagnosis and mortality prediction in patients hospitalized from the emergency department. Crit Care 2013;17:R29.
43. Di Somma S. NGAL use & experiences for AKI detection in the emergency department. Presentation in A Lewington (Chair), NGAL: ready for routine clinical use? An international perspective. Symposium at 31st International Vicenza Course on Critical Care Nephrology, Vicenza, Italy, 2013.
44. Kellermann AL. Crisis in the emergency department. N Engl J Med 2006;355:1300-3.